Volume 24, Number 9—September 2018
Use of Favipiravir to Treat Lassa Virus Infection in Macaques
|Study, no. animals||Treatment||Frequency†||Dose, mg/kg||Loading dose, mg/kg||Total daily dose, mg/kg||Survived/total, no.|
|4||Placebo||Every 24 h||Volume equivalent||Volume equivalent||Volume equivalent||0/4|
||Every 24 h
|4||Placebo||Every 8 h||Volume equivalent.||Volume equivalent||Volume equivalent||0/4|
|4||Favipiravir||Every 8 h||50||300||150||0/4|
*All animals were challenged with a previously determined lethal dose of 104 50% tissue culture infective dose of Lassa virus (strain Josiah) via intramuscular injection. At day 4 after infection, a time coinciding with the earliest onset of detectable viremia, treatment with placebo or drug was initiated by intravenous injection of the loading dose followed by daily (days 5–17) subcutaneous dosing. Animals were examined daily for clinical signs of disease, and samples were taken for hematologic, blood chemistry, and virologic analyses at 12 times throughout the study, beginning on the day of virus challenge and ending on day 56 after infection.
†For 14 d.
- Page created: June 11, 2018
- Page last updated: June 11, 2018
- Page last reviewed: June 11, 2018
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)